Your browser doesn't support javascript.
loading
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Jhaveri, Komal; Chang, Matthew T; Juric, Dejan; Saura, Cristina; Gambardella, Valentina; Melnyk, Anton; Patel, Manish R; Ribrag, Vincent; Ma, Cynthia X; Aljumaily, Raid; Bedard, Philippe L; Sachdev, Jasgit C; Dunn, Lara; Won, Helen; Bond, John; Jones, Surai; Savage, Heidi M; Scaltriti, Maurizio; Wilson, Timothy R; Wei, Michael C; Hyman, David M.
Afiliação
  • Jhaveri K; Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, New York. jhaverik@mskcc.org.
  • Chang MT; Weill Cornell Medical College, New York, New York.
  • Juric D; Genentech, Inc., South San Francisco, California.
  • Saura C; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Gambardella V; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Melnyk A; INCLIVA Biomedical Research Institute, Hospital Clinico Universitario of Valencia, and CIBERONC, Valencia/Madrid, Spain.
  • Patel MR; Texas Oncology-Abilene, Abilene, Texas.
  • Ribrag V; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida.
  • Ma CX; Institut Gustave Roussy, Villejuif, France.
  • Aljumaily R; Washington University School of Medicine, St. Louis, Missouri.
  • Bedard PL; University of Oklahoma - Stephenson Cancer Center, Oklahoma City, Oklahoma.
  • Sachdev JC; Princess Margaret Cancer Centre, Division of Medical Oncology & Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Dunn L; HonorHealth Research Institute/TGen, Scottsdale, Arizona.
  • Won H; Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, New York.
  • Bond J; Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, New York.
  • Jones S; Genentech, Inc., South San Francisco, California.
  • Savage HM; GCE Solutions Inc., Bloomington, Illinois.
  • Scaltriti M; Genentech, Inc., South San Francisco, California.
  • Wilson TR; Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, New York.
  • Wei MC; Genentech, Inc., South San Francisco, California.
  • Hyman DM; Genentech, Inc., South San Francisco, California.
Clin Cancer Res ; 27(2): 447-459, 2021 01 15.
Article em En | MEDLINE | ID: mdl-33148674
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazepinas / Classe I de Fosfatidilinositol 3-Quinases / Imidazóis / Mutação / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazepinas / Classe I de Fosfatidilinositol 3-Quinases / Imidazóis / Mutação / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos